Delving into the Latest Updates on Ceralifimod with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists), S1PR5 agonists(Sphingosine 1-phosphate receptor Edg-8 agonists)

Therapeutic Areas

Immune System DiseasesNervous System Diseases

Active Indication-

Inactive Indication

Multiple Sclerosis, Relapsing-Remitting

Originator Organization

Ono Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Ono Pharma USA, Inc.

EMD Serono, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC27H33NO4

InChIKeyQDDQIPUKAXBMBX-UHFFFAOYSA-N

CAS Registry891859-12-4

ONO-4641, 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid (ceralifimod), is a second-generation sphingosine 1-phosphate receptor agonist selective for sphingosine 1-phosphate receptors 1 and 5, and has clinical effects in multiple sclerosis. The objective of the present study was to explore other potential indications for ONO-4641 based on its immunomodulatory effects. ONO-4641 was tested in non-obese diabetic (NOD) mice, an animal model of spontaneous type 1 diabetes mellitus, an autoimmune disease with unmet medical needs. ONO-4641 at a dose of 0.1 mg/kg prevented the onset of diabetes mellitus in NOD mice. Furthermore, ONO-4641 at doses of 0.03 and 0.1 mg/kg decreased diabetic prevalence in NOD mice after the onset of diabetes mellitus in a dose-dependent manner. Histopathological analysis demonstrated that insulin-positive areas in the islets of mice administered 0.03 and 0.1 mg/kg ONO-4641 showed a tendency of high values although they were not significantly different from the Control group, which was treated with vehicle. These observations suggest ONO-4641 may delay the onset and progression of type 1 diabetes mellitus.

01 Feb 2021·Journal of Pharmacology and Experimental TherapeuticsQ3 · MEDICINE

Sphingosine 1-Phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated Aplastic Anemia in a Mouse Model

Q3 · MEDICINE

Article

Author: Komiya, Takaki ; Gohda, Masashi ; Shioya, Hiroki ; Katsumata, Seishi

ONO-4641 is a second-generation sphingosine 1-phosphate (S1P) receptor modulator that exhibits selectivity for S1P receptors 1 and 5. Treatment with ONO-4641 leads to a reduction in magnetic resonance imaging disease measures in patients with relapsing-remitting multiple sclerosis. The objective of this study was to explore the potential impact of ONO-4641 treatment based on its immunomodulatory effects. Severe aplastic anemia is a bone marrow (BM) failure disease typically caused by aberrant immune destruction of blood progenitors. Although the T helper type 1-mediated pathology is well described for aplastic anemia, the molecular mechanisms driving disease progression remain undefined. We evaluated the efficacy of ONO-4641 in a mouse model of aplastic anemia. ONO-4641 reduced the severity of BM failure in a dose-dependent manner, resulting in higher blood and BM cell counts. By evaluating the mode of action, we found that ONO-4641 inhibited the infiltration of donor-derived T lymphocytes to the BM. ONO-4641 also induced the accumulation of hematopoietic stem cells in the BM of model mice. These observations indicate, for the first time, that S1P receptor modulators demonstrate efficacy in the mouse model of aplastic anemia and suggest that treatment with ONO-4641 might delay the progression of aplastic anemia. SIGNIFICANCE STATEMENT: ONO-4641 is a second-generation sphingosine 1-phosphate (S1P) receptor modulator selective for S1P receptors 1 and 5. In this study, we demonstrated that ONO-4641 regulates the trafficking of T lymphocytes along with hematopoietic stem and progenitor cells, leading to alleviation of pancytopenia and destruction of bone marrow in a bone marrow failure-induced mouse model mimicking human aplastic anemia.

01 Nov 2018·Mucosal ImmunologyQ1 · MEDICINE

Sphingosine 1-phosphate receptor modulator ONO-4641 stimulates CD11b+Gr-1+ cell expansion and inhibits lymphocyte infiltration in the lungs to ameliorate murine pulmonary emphysema

Q1 · MEDICINE

Article

Author: Kamata, Hirofumi ; Namkoong, Ho ; Asakura, Takanori ; Kagawa, Shizuko ; Yagi, Kazuma ; Hasegawa, Naoki ; Komiya, Takaki ; Okamori, Satoshi ; Suzuki, Shoji ; Tasaka, Sadatomo ; Hegab, Ahmed E ; Betsuyaku, Tomoko ; Kihara, Akio ; Ishii, Makoto ; Hashimoto, Takafumi

Sphingolipids play a pivotal role in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, little is known about the precise roles of sphingosine-1-phosphate (S1P), a bioactive sphingolipid metabolite, and its receptor modulation in COPD. In this study, we demonstrated that the S1P receptor modulator ONO-4641 induced the expansion of lung CD11b⁺Gr-1⁺ cells and lymphocytopenia in naive mice. ONO-4641-expanded CD11b⁺Gr-1⁺ cells showed higher arginase-1 activity, decreased T cell proliferation, and lower IFN-γ production in CD3⁺ T cells, similar to the features of myeloid-derived suppressor cells. ONO-4641 treatment decreased airspace enlargement in elastase-induced and cigarette smoke-induced emphysema models and attenuated emphysema exacerbation induced by post-elastase pneumococcal infection, which was also associated with an increased number of lung CD11b⁺Gr-1⁺ cells. Adoptive transfer of ONO-4641-expanded CD11b⁺Gr-1⁺ cells protected against elastase-induced emphysema. Lymphocytopenia observed in these models likely contributed to beneficial ONO-4641 effects. Thus, ONO-4641 attenuated murine pulmonary emphysema by expanding lung CD11b⁺Gr-1⁺ cell populations and inducing lymphocytopenia. The S1P receptor might be a promising target for strategies aimed at ameliorating pulmonary emphysema progression.

100 Deals associated with Ceralifimod

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16123

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	Phase 2	UA	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	ES	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	JP	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	CA	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	JP	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	UA	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	CZ	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Phase 2	CZ	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Preclinical	ES	Ono Pharma USA, Inc.	01 Mar 2010
Multiple Sclerosis, Relapsing-Remitting	Preclinical	CA	Ono Pharma USA, Inc.	01 Mar 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01226745 (CTgov)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	340	ONO-4641 (ONO-4641 0.10 mg - 0.10 mg)	wzbxpofrnb(rhxpsljouq) = jvdkkvbwwe vkozrmclrm (lrysusgzbi, suqltwpaki - tttcrnypul) View more	-	12 Jul 2016
				ONO-4641 (ONO-4641 0.05 mg - 0.05 mg)	wzbxpofrnb(rhxpsljouq) = psptohowyt vkozrmclrm (lrysusgzbi, hdaucxebgr - jxzcjnedmr) View more
NCT01081782 (DreaMS, AAN2013)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	-	Placebo	(eunqmjpwqy) = gbyxoxfqrh fdgqnxoyjl (xzqewiicsp ) View more	Positive	12 Feb 2013
				ONO-4641 0.05 mg	(eunqmjpwqy) = zrjbsgklzs fdgqnxoyjl (xzqewiicsp ) View more
DreaMS (AAN2013)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	-	Placebo	ojrojbzvog(rdljecflyp): relative reduction = 70 (95% CI, 54 - 81)	-	12 Feb 2013
				ONO-4641 0.05 mg
DreaMS study (ECTRIMS2013)	Not Applicable	Multiple Sclerosis	360	Placebo/0.05 mg ONO-4641	yghgfeezva(ekqcnbyixs) = bzzvowkwti yjtufhyzpe (vxrvqrwrue )	-	30 Sep 2013
				Placebo/0.10 mg ONO-4641	yghgfeezva(ekqcnbyixs) = gwgwfbiwng yjtufhyzpe (vxrvqrwrue )
DreaMS study (ECTRIMS2013)	Not Applicable	Multiple Sclerosis	343	ONO-4641 0.10mg	(ciqeuzznri): ARR = 0.16 (95% CI, 0.08 - 0.33)	-	30 Sep 2013
				Placebo/ONO-4641 0.05mg